Regenxbio and its Chief Medical Officer Stephen Pakola are named as defendants in a securities class action alleging the company’s public statements about the safety of RGX-111 concealed material risks from investors. The complaint alleges Pakola repeatedly said RGX-111 was “well-tolerated” and that there were “no drug-related serious adverse events” in disclosures from February 2022 to November 2023. After information emerged on January 28, 2026, Regenxbio shares fell USD 2.4, or 18%, to USD 11.01. The suit also asserts a controlling-person claim against Pakola under Section 20(a) of the Securities Exchange Act.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603110900PR_NEWS_USPR_____NY07396) on March 11, 2026, and is solely responsible for the information contained therein.